[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  zohm [@zohmbastic](/creator/twitter/zohmbastic) on x 7901 followers Created: 2025-07-02 11:23:40 UTC $ATAI Canaccord raised the firm's price target on Atai Life Sciences to $XX from $XX and keeps a Buy rating on the shares. The firm believes shares remain significantly undervalued following the release of solid Phase 2b data for BPL-003 (intranasal mebufotenin or 5-MeO-DMT) for treatment-resistant depression (TRD). They view the results as very encouraging as BPL-003 hit its primary and all key secondary endpoints convincingly. These results pave the way for the recently-announced ATAI-Beckley merger to close, which is on track for 2H25. XXXXX engagements  **Related Topics** [stocks](/topic/stocks) [$atai](/topic/$atai) [atai life](/topic/atai-life) [stocks bitcoin treasuries](/topic/stocks-bitcoin-treasuries) [Post Link](https://x.com/zohmbastic/status/1940370786918822269)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
zohm @zohmbastic on x 7901 followers
Created: 2025-07-02 11:23:40 UTC
$ATAI Canaccord raised the firm's price target on Atai Life Sciences to $XX from $XX and keeps a Buy rating on the shares. The firm believes shares remain significantly undervalued following the release of solid Phase 2b data for BPL-003 (intranasal mebufotenin or 5-MeO-DMT) for treatment-resistant depression (TRD). They view the results as very encouraging as BPL-003 hit its primary and all key secondary endpoints convincingly. These results pave the way for the recently-announced ATAI-Beckley merger to close, which is on track for 2H25.
XXXXX engagements
Related Topics stocks $atai atai life stocks bitcoin treasuries